Norinchukin Bank The Buys 1,137 Shares of IQVIA Holdings Inc. $IQV

Norinchukin Bank The increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 13.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,385 shares of the medical research company’s stock after buying an additional 1,137 shares during the quarter. Norinchukin Bank The’s holdings in IQVIA were worth $1,655,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Sowell Financial Services LLC purchased a new stake in IQVIA in the first quarter worth $305,000. Mather Group LLC. increased its stake in IQVIA by 83.5% in the first quarter. Mather Group LLC. now owns 769 shares of the medical research company’s stock worth $136,000 after purchasing an additional 350 shares during the period. Private Advisor Group LLC increased its stake in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after purchasing an additional 566 shares during the period. Park Avenue Securities LLC increased its stake in IQVIA by 40.4% in the first quarter. Park Avenue Securities LLC now owns 5,425 shares of the medical research company’s stock worth $956,000 after purchasing an additional 1,562 shares during the period. Finally, Wealth Enhancement Advisory Services LLC increased its stake in shares of IQVIA by 34.5% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 13,259 shares of the medical research company’s stock valued at $2,338,000 after buying an additional 3,398 shares during the period. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Transactions at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total transaction of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. The trade was a 17.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the business’s stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at $557,352.30. The trade was a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on IQV shares. Robert W. Baird raised their price target on IQVIA from $159.00 to $196.00 and gave the company a “neutral” rating in a research note on Wednesday, July 23rd. Redburn Partners set a $188.00 price target on IQVIA in a research note on Friday, May 23rd. JPMorgan Chase & Co. cut their price target on IQVIA from $232.00 to $177.00 and set an “overweight” rating on the stock in a research note on Monday, May 19th. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, Hsbc Global Res lowered IQVIA from a “strong-buy” rating to a “hold” rating in a research note on Friday, April 25th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $228.62.

IQVIA Price Performance

IQV opened at $190.9870 on Friday. The business’s 50-day moving average is $173.70 and its two-hundred day moving average is $168.51. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $32.47 billion, a PE ratio of 27.64, a price-to-earnings-growth ratio of 2.04 and a beta of 1.30.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the previous year, the firm earned $2.64 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. Research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.